| androst-5-ene-3 beta,17 beta-diol | <chemical> An adrenal-derived oestrogenic metabolite of dhea. Evidence exist for its use as an endocrine regulator of immune response. Pharmacological action: anabolic steroids. Chemical name: Androst-5-ene-3,17-diol, (3beta,17beta)- (12 Dec 1998) |
|---|---|
| beta-1,3-galactosyl-0-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase | <enzyme> Capable of adding a glcnac residue to g1cnacman(3)g1cnac; from mung bean seedlings Registry number: EC 2.4.1.146 Synonym: n-acetylglucosaminyltransferase II, gal3-(glcnac6)galnac-mucin (glcnac--gal)3-glcnactransferase (26 Jun 1999) |
| beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-acetylglucosaminyl transferase | <enzyme> With EC 2.4.1.148 this is called beta6-glcnac-transferase b Registry number: EC 2.4.1.102 Synonym: gal3-galnac-mucin-6-glcnac transferase, udp-glcnac-gal1-3galnac-r-(glcnac to galnac)-beta1-6glcnac transferase, core 2 glcnac transferase, core 2-n-acetylglucosaminyltransferase, core 2 beta6-gn-t (26 Jun 1999) |
| beta-1,4-mannosyl-glycoprotein beta-1,4-N-acetylglucosaminyltransferase | <enzyme> Induced in preneoplastic stage of liver carcinogenesis promoted by orotic acid in rats; adds "bisecting n-acetylglucosaminyl residue in beta 1,4 linkage to the beta-linked mannose of the core of asparagine-linked oligosaccharides Registry number: EC 2.4.1.144 Synonym: n-acetylglucosaminyltransferase III, udpgnac-glycopeptide beta4-n-acetylglucosaminyl transferase III, udpgnac-magtransferase III, udp-n-acetylglucosamine-beta-d-mannoside beta-1,4-n-acetylglucosaminyltransferase III (26 Jun 1999) |
| beta-hydroxy-beta-methylglutaryl-CoA | -OOCCH2C(OH)(CH3)CH2COS-CoA;a key intermediate in the synthesis of ketone bodies and of steroids. Synonym: 3-hydroxy-3-methylglutaryl-CoA. Beta-hydroxy-beta-methylglutaryl-lyase, an enzyme, found primarily in liver and rumen epithelium that catalyses the formation of acetyl-CoA and acetoacetate from beta-hydroxy-beta-methylglutaryl-CoA; a key step in ketogenesis; a deficiency of this enzyme leads to episodes of severe metabolic acidosis without ketosis. Beta-hydroxy-beta-methylglutaryl-reductase, an enzyme that catalyses the rate-limiting step of cholesterol biosynthesis, beta-hydroxy-beta-methylglutaryl-CoA + 2NADPH + 2H+ → mevalonate + 2NADP+ + coenzyme A. Beta-hydroxy-beta-methylglutaryl-synthase, an enzyme in mitochondria that catalyses the reaction of acetyl-CoA with acetoacetyl-CoA and water to form beta-hydroxy-beta-methylglutaryl-CoA and coenzyme A, a step required for both ketogenesis and steroidogenesis to occur. (05 Mar 2000) |
| beta-n-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase | <enzyme> An enzyme that catalyses the transfer of galactose from udp-galactose to a specific glycoprotein receptor, 2-acetamido-2-deoxy-d-glucosyl-glycopeptide, during glycopeptide synthesis. Chemical name: UDPgalactose:N-acetyl-beta-D-glucosaminylglycopeptide beta-1,4-galactosyltransferase Registry number: EC 2.4.1.38 (12 Dec 1998) |
| beta, or beta-value | <radiobiology> Ratio of plasma kinetic pressure to magnetic-field pressure, proportional to the ratio of plasma kinetic energy density to magnetic field energy density. Beta is usually measured relative to the total, local field (loosely called beta toroidal), but sometimes the plasma pressure relative to only the poloidal component of the field (beta poloidal) or relative to some external field (like the maximum field at the magnetic coils) is more useful. There is also a normalised beta (beta_N) of interest when discussing the beta limit. (lots of help from Art Carlson with the above.) Because the cost of a reactor is strongly influenced by the strength of the magnetic field that must be provided, beta values are directly related to the economics of fusion power production. Beta is usually expressed as a percentage, with 5% generally believed to be the minimum value required for an economical fusion reactor. See: pressure, kinetic pressure, magnetic pressure, second stability. (09 Oct 1997) |
| UDP-GalNAc-beta-galactose beta 1,4-N-acetylgalactosaminyltransferase | <enzyme> Consider also EC 2.4.1.92 Registry number: EC 2.4.1.- Synonym: beta-1,4-n-acetylgalactosaminyltransferase, 4-galnactransferase, udp-n-acetylgalactosamine-beta-galactose beta 1,4-n-acetylgalactosaminyltransferase, (1-4)-n-acetyl-beta-d-galactosaminyltransferase, galnact-1 (26 Jun 1999) |
| 5 alpha-androstane-3 beta,17 beta-diol 6 alpha-hydroxylase | <enzyme> Requires NADPH, found in rat prostatic microsomes Registry number: EC 1.14.13.- Synonym: artdl 6 alpha-hydroxylase (26 Jun 1999) |
| 5 alpha-androstane 3 beta,17 beta-diol 7 alpha-hydroxylase | <enzyme> Requires NADPH, found in rat prostate microsomes Registry number: EC 1.14.13.- Synonym: artdl 7 alpha-hydroxylase (26 Jun 1999) |
| adrenal cortex injection | An obsolete treatment involving the parenteral administration of extract of the adrenal cortex; formerly used in treatment of Addison's disease. (05 Mar 2000) |
| bolus injection | <procedure> The injection of a drug (or drugs) in a high quantity (called a bolus) at once, the opposite of gradual administration (as in intravenous infusion). (18 Nov 1997) |
| regular insulin injection | A preparation that may contain 20, 40, 80, 100, or 500 USP insulin units per ml, although the trend is toward standardizing all insulin preparations at 100 units per ml; it is administered subcutaneously, occasionally intravenously, and has a rapid onset of action, has a brief duration (5 to 7 hours), and is compatible for mixing with long-acting insulin preparations; used in the treatment of diabetic acidosis and insulin coma. Synonym: regular insulin injection. (05 Mar 2000) |
| Ringer's injection | A sterile solution of sodium chloride, potassium chloride, and calcium chloride, containing in each 100 ml between 820 and 900 mg of sodium chloride, between 25 and 35 mg of potassium chloride, and between 30 and 37 mg of calcium chloride; used intravenously as a fluid and electrolyte replenisher. (05 Mar 2000) |
| water for injection | Water purified by distillation for the preparation of products for parenteral use. (05 Mar 2000) |